S&P Futures
4,155.50 -20.25 (-0.48%) Dow Futures
34,064.00 -142.00 (-0.42%) Nasdaq Futures
12,725.50 -51.25 (-0.40%) Russell 2000 Futures
1,964.80 -14.50 (-0.73%) Crude Oil
77.75 +0.61 (+0.79%) Gold
1,889.50 +4.70 (+0.25%)
Bluejay Diagnostics, Inc. (BJDX)
After hours:
- Simply Wall St.
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) drops to US$14m and insiders who purchased earlier this year lose another US$65k
Insiders who acquired US$183k worth of Bluejay Diagnostics, Inc.'s ( NASDAQ:BJDX ) stock at an average price of US$1.09...
- GlobeNewswire
Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results
ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2022. “The last quarter focused on increasing awareness of Bluejay’s Symphony IL-6 test by directly engaging the
- GlobeNewswire
Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that Neil Dey, Chief Executive Officer, and Kenneth Fisher, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022, at the Lotte Palace Ho
